Factor Xa (FXa) is the key serine protease of the coagulation cascade at the point of convergence of the intrinsic and extrinsic pathways leading to the formation of thrombin and is the established target of anticoagulation therapy (1) . Direct oral anticoagulants targeting FXa are widely used in clinical practice for prevention and treatment of thrombotic events.
Increasing evidence suggests that FXa exerts nonhemostatic cellular effects that are mediated mainly through protease-activated receptors-1 (PAR-1) and PAR-2, which are expressed in cardiac myocytes and fibroblasts (1, 2) . Activation of PAR-1 and PAR-2 have been implicated in pathophysiological conditions such as atherosclerosis, inflammation, and fibrosis, raising the possibility of pleiotropic antifibrotic and anti-inflammatory cardioprotective effects of direct oral anticoagulants targeting FXa (1, 2) .
In this issue of JACC: Basic to Translational Science, Guo et al. (2) In the COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial (6), 
